Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear. METHODS: We randomly assigned 16,492 patients with type 2 diabetes who had a history of, or were at risk for, cardiovascular events to receive saxagliptin or placebo and followed them for a median of 2.1 years. Physicians were permitted to adjust other medications, including antihyperglycemic agents. The primary end point was a composite of cardiovascular death, myocardial infarction, or ischemic stroke. RESULTS: A primary end-point event occurred in 613 patients in the saxagliptin group and in 609 patients in the placebo group (7.3% and 7.2%, respectively, according to 2-year Kaplan-Meier estimates; hazard ratio with saxagliptin, 1.00; 95% confidence interval [CI], 0.89 to 1.12; P=0.99 for superiority; P<0.001 for noninferiority); the results were similar in the "on-treatment" analysis (hazard ratio, 1.03; 95% CI, 0.91 to 1.17). The major secondary end point of a composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, coronary revascularization, or heart failure occurred in 1059 patients in the saxagliptin group and in 1034 patients in the placebo group (12.8% and 12.4%, respectively, according to 2-year Kaplan-Meier estimates; hazard ratio, 1.02; 95% CI, 0.94 to 1.11; P=0.66). More patients in the saxagliptin group than in the placebo group were hospitalized for heart failure (3.5% vs. 2.8%; hazard ratio, 1.27; 95% CI, 1.07 to 1.51; P=0.007). Rates of adjudicated cases of acute and chronic pancreatitis were similar in the two groups (acute pancreatitis, 0.3% in the saxagliptin group and 0.2% in the placebo group; chronic pancreatitis, <0.1% and 0.1% in the two groups, respectively). CONCLUSIONS: DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased. Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes. (Funded by AstraZeneca and Bristol-Myers Squibb; SAVOR-TIMI 53 ClinicalTrials.gov number, NCT01107886.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Trials of HF outcomes with dapagliflozin and empagliflozin, enrolling up to 50% of participants with type 2 diabetes, report reduction in cardiovascular death and improvement of HF among patients with HF with reduced ejection fraction and HF with preserved ejection fraction, respectively, independent of diabetes status, compared with placebo.66–69,88”
From Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review (2025) · cites this paper as [69]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In 4 trials to date, the DPP4 inhibitors have been shown to be neutral in terms of cardiovascular outcomes.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [186]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of SAVOR-TIMI 53 (NCT01107886) and EXAMINE (NCT00968708) were recently released and showed no increased risk of cardiovascular events with the DPP-4 inhibitors saxagliptin96 and alogliptin97, respectively.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [96]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Not all DPP4 inhibitors are associated with higher rates of HF (Table 8).16 -24,184-186”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [19]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Self-citationThe Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Cited by
Items 401–500 of 1,020
Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
Lim, L.-L., Chow, E., & Chan, J. C. N. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00776-2 · Cited by 91
Chen, X., He, Z., Zhou, Z., Yang, T., Zhang, X., Yang, Y., Duan, W., & Zhou, S. (2015) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12455 · Cited by 86
“patients enrolled in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI 53) trial.(157) Although this study did not find increased rates of death or other major cardiovascular risks, including heart attack or stroke, in patients…”
BackgroundMethodManigrasso, M. B., Rabbani, P. S., Egaña-Gorroño, L., Quadri, N., Frye, L., Zhou, B., Reverdatto, S., Ramirez, L. S., Dansereau, S. J., Pan, J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf7084 · Cited by 94
Hwangbo, C., Wu, J., Papangeli, I., Adachi, T., Sharma, B., Park, S., Zhao, L., Ju, H., Go, G.-W., Cui, G., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aad4000 · Cited by 87
Emerging treatments for post-transplantation diabetes mellitus
Jenssen, T., & Hartmann, A. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.59 · Cited by 90
Eriksson, J. W., Bodegard, J., Nathanson, D., Thuresson, M., Nyström, T., & Norhammar, A. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.055 · Cited by 90
“[8] Scirica BM, Bhatt DL, Braunwald E, et al.”
BackgroundA Pragmatic Approach to Inpatient Diabetes Management during the COVID-19 Pandemic
Korytkowski, M., Antinori-Lent, K., Drincic, A., Hirsch, I. B., McDonnell, M. E., Rushakoff, R., & Muniyappa, R. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa342 · Cited by 89
“At this time, there is no data demonstrating either harmful or beneficial impact of these agents in patients with COVID-19 (42,44) The use of saxagliptin and alogliptin is not recommended due to concerns for an increase incidence of heart failure (HF) (45,46).”
BackgroundCardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis
Savarese, G., Perrone-Filardi, P., D'Amore, C., Vitale, C., Trimarco, B., Pani, L., & Rosano, G. M. C. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.12.017 · Cited by 90
Swoboda, P. P., McDiarmid, A. K., Erhayiem, B., Ripley, D. P., Dobson, L. E., Garg, P., Musa, T. A., Witte, K. K., Kearney, M. T., Barth, J. H., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005539 · Cited by 89
Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J. M., Capodanno, D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.10.016 · Cited by 125
Erion, D. M., Park, H., & Lee, H. (2016) · BMB Reports · doi:10.5483/bmbrep.2016.49.3.268 · Cited by 101
“any cardiovascular benefit and some DPP-IV inhibitors are associated with increased hospitalization due to heart failure (65).”
BackgroundZhao, H., Wang, L., Wei, R., Xiu, D., Tao, M., Ke, J., Liu, Y., Yang, J., & Hong, T. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12291 · Cited by 88
Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond
Martens, P., Mathieu, C., & Verbrugge, F. H. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0522-x · Cited by 99
Novel Diabetes Drugs and the Cardiovascular Specialist
Sattar, N. A., Petrie, M. C., Zinman, B., & Januzzi, J. L. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.014 · Cited by 95
“The reduction in heart failure events was particularly clinically relevant as drugs from other classes of glucose-lowering drugs with very different mechanisms of action (in particular saxagliptin and rosiglitazone) had previously been found to be associated with an increase in hospitalizations for heart failure (15,1…”
BackgroundIntensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus
Kirkman, M. S., Mahmud, H., & Korytkowski, M. T. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.002 · Cited by 98
Bergmark, B. A., Bhatt, D. L., McGuire, D. K., Cahn, A., Mosenzon, O., Steg, P. G., Im, K., Kanevsky, E., Gurmu, Y., Raz, I., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.040144 · Cited by 88
Self-citationA review of dipeptidyl peptidase‐4 inhibitors. Hot topics from randomized controlled trials
Deacon, C. F. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13135 · Cited by 81
“27), although this was not associated with any increase in mortality.(9) Further analysis indicated that the increased risk became evident during the first 12 months, stabilizing thereafter, with event rates overall being highest in those patients who had a history of heart failure, impaired renal function or elevated…”
BackgroundTomović, K., Lazarević, J., Kocic, G. M., Deljanin-Ilić, M., Anderluh, M., & Šmelcerović, A. (2018) · Medicinal Research Reviews · doi:10.1002/med.21513 · Cited by 90
Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial
Leiter, L. A., Teoh, H., Braunwald, E., Mosenzon, O., Cahn, A., Kumar, K. M. P., Smahelova, A., Hirshberg, B., Stahre, C., Frederich, R., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2868 · Cited by 87
Self-citationPerspectives on Treatment for Nonalcoholic Steatohepatitis
Lassailly, G., Caiazzo, R. J., Pattou, F. N., & Mathurin, P. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.004 · Cited by 94
Norouzi, S., Adulcikas, J., Sohal, S. S., & Myers, S. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0394-0 · Cited by 92
“Dipeptidylpeptidase-4 inhibitors Heart failure [83].”
McGurnaghan, S. J., Blackbourn, L. A. K., Mocevic, E., Panton, U. H., McCrimmon, R. J., Sattar, N. A., Wild, S. H., & Colhoun, H. M. (2018) · Diabetic Medicine · doi:10.1111/dme.13825 · Cited by 87
“Drug labels and clinical guidelines are being updated accordingly [9 – 16], and it is hoped that the target of lowering HbA 1c in Type 2 diabetes and the major goal of lowering the cause of excess death will be increasingly achieved.”
Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism
Trzaskalski, N. A., Fadzeyeva, E., & Mulvihill, E. E. (2020) · Clinical Medicine Insights: Endocrinology and Diabetes · doi:10.1177/1179551420912972 · Cited by 85
“Dipeptidyl peptidase 4 inhibition stimulates distal tubular natriuresis and increases in circulating SDF-1alpha(1-67) in patients with type 2 diabetes.”
BackgroundNetwork Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury
Zhao, M., Sun, S., Huang, Z., Wang, T., & Tang, H. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11220720 · Cited by 82
Abudureyimu, M., Luo, X., Wang, X., Sowers, J. R., Wang, W., Ge, J., Ren, J. T., & Zhang, Y. (2022) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjac028 · Cited by 97
A polygenic risk score predicts atrial fibrillation in cardiovascular disease
Marston, N., Garfinkel, A. C., Kamanu, F., Melloni, G. E. M., Roselli, C., Jarolím, P., Berg, D. D., Bhatt, D. L., Bonaca, M. P., Cannon, C. P., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac460 · Cited by 91
Self-citationOxyntomodulin: actions and role in diabetes
Holst, J. J., Albrechtsen, N. J. W., Gabe, M. B. N., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.09.018 · Cited by 86
Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF
Vaduganathan, M., Fonarow, G. C., Greene, S. J., DeVore, A. D., Kavati, A., Sikirica, S., Albert, N. M., Duffy, C. I., Hill, C. L., Patterson, J. H., et al. (2020) · JACC: Heart Failure · doi:10.1016/j.jchf.2019.12.015 · Cited by 86
Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease
Lonardo, A., Ballestri, S., Targher, G., & Loria, P. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.965143 · Cited by 86
The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
Kim, N.-H., Yu, T., & Lee, D. H. (2014) · BioMed Research International · doi:10.1155/2014/368703 · Cited by 94
GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
Simó, R., & Hernández, C. (2017) · Diabetes · doi:10.2337/db16-1364 · Cited by 86
Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus
Sesti, G., Avogaro, A., Belcastro, S., Bonora, B. M., Croci, M., Daniele, G., Dauriz, M., Dotta, F., Formichi, C., Frontoni, S., et al. (2019) · Acta Diabetologica · doi:10.1007/s00592-018-1271-3 · Cited by 94
Is Hemoglobin A1c the Right Outcome for Studies of Diabetes?
Lipska, K. J., & Krumholz, H. M. (2017) · JAMA · doi:10.1001/jama.2017.0029 · Cited by 85
The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors
Filippatos, T. D., Athyros, V. G., & Elisaf, M. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.907274 · Cited by 95
“This effect may be associated with the increased frequency of hospitalization for heart failure with saxagliptin in the SAVOR-TIMI 53 trial [75].”
BackgroundInfluentialDipeptidyl Peptidase-4 Regulation of SDF-1/CXCR4 Axis: Implications for Cardiovascular Disease
Zhong, J., & Rajagopalan, S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00477 · Cited by 83
“Several recent large scale clinical trials have indicated that unlike most other oral anti-diabetic drugs that promote cardiovascular disease, DPP4 inhibitors are safe from cardiovascular standpoint despite lack of evidence showing beneficial effect (96) (97) (98) .”
BackgroundDiabetes and Risk of Arterial Stiffness: A Mendelian Randomization Analysis
Xu, M., Huang, Y. F., Xie, L., Peng, K., Ding, L., Lin, L., Po, W., Hao, M., Chen, Y., Sun, Y., et al. (2016) · Diabetes · doi:10.2337/db15-1533 · Cited by 89
Patorno, E., Gopalakrishnan, C., Franklin, J. M., Brodovicz, K. G., Masso‐Gonzalez, E., Bartels, D. B., Liu, J., & Schneeweiss, S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13184 · Cited by 84
Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study
Faillie, J.-L., Azoulay, L., Patenaude, V., Hillaire-Buys, D., & Suissa, S. (2014) · BMJ · doi:10.1136/bmj.g2780 · Cited by 83
Predicting and preventing heart failure in type 2 diabetes
Pandey, A., Khan, M. S., Patel, K. V., Bhatt, D. L., & Verma, S. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00128-6 · Cited by 92
Self-citationJohnston, R., Uthman, O. A., Cummins, E., Clar, C., Royle, P., Colquitt, J. L., Tan, B. K., Clegg, A. J., Shantikumar, S., Court, R. A., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21020 · Cited by 92
“l SAVOUR for saxagliptin (The Saxagliptin assessment Of Vascular Outcomes Recorded in patients with diabetes mellitus).(140) l EXAMINE for alogliptin (Examination of cardiovascular outcomes with alogliptin versus standard of care in patients with type 2 diabetes mellitus and acute coronary syndrome).”
BackgroundPaneni, F., & Lüscher, T. F. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.015 · Cited by 83
Tang, H., Li, G., Zhao, Y., Wang, F., Gower, E. W., Shi, L., & Wang, T. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13232 · Cited by 78
Cardiovascular outcome trials of glucose-lowering medications: an update
Home, P. (2019) · Diabetologia · doi:10.1007/s00125-018-4801-1 · Cited by 82
Garg, V., Verma, S., & Connelly, K. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.005 · Cited by 82
Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update
Booth, G. L., Lipscombe, L. L., Butalia, S., Dasgupta, K., Eurich, D. T., Goldenberg, R., Khan, N., MacCallum, L., Shah, B. R., Simpson, S. H., et al. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.09.003 · Cited by 90
Rosenstock, J., Perkovic, V., Alexander, J. H., Cooper, M. E., Marx, N., Pencina, M. J., Toto, R. D., Wanner, C., Zinman, B., Baanstra, D., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0682-3 · Cited by 83
“However, the incidence of hospitalization for heart failure was statistically increased in the SAVOR-TIMI 53 trial of saxagliptin versus placebo [6] and numerically increased in the EXAMINE trial of alogliptin versus placebo [23]; whereas no effect on the incidence of heart failure hospitalization was observed in the…”
BackgroundSelf-citationJoubert, M., Manrique, A., Cariou, B., & Prieur, X. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.07.003 · Cited by 81
Rosenstock, J., Marx, N., Neubacher, D., Seck, T., Patel, S., Woerle, H.-J., & Johansen, O. E. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0215-2 · Cited by 82
“The unexpected finding of an increased risk of CHF in these trials merits further careful evaluation [12,14,15].”
InfluentialNyström, T., Bodegard, J., Nathanson, D., Thuresson, M., Norhammar, A., & Eriksson, J. W. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12889 · Cited by 84
“Cancer 1897 (15) 6018 (24) 1780 (16) 1791 (16) .”
Nelson, A. J., Pagidipati, N. J., Aroda, V. R., Cavender, M. A., Green, J. B., Lopes, R. D., Al-Khalidi, H., Gaynor, T., Kaltenbach, L. A., Kirk, J. K., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053766 · Cited by 79
Self-citationMaking Sense of Statistics in Clinical Trial Reports
Pocock, S., McMurray, J. J. V., & Collier, T. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.014 · Cited by 86
An update on DPP-4 inhibitors in the management of type 2 diabetes
Cahn, A., Cernea, S., & Raz, I. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1257608 · Cited by 83
Self-citationEsposito, G., Cappetta, D., Russo, R., Rivellino, A., Ciuffreda, L. P., Roviezzo, F., Piegari, E., Berrino, L., Rossi, F., Angelis, A. D., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13686 · Cited by 87
“In particular, the risk of hospitalization for HF was higher with saxagliptin (Scirica et al., 2013), while alogliptin showed only a trend toward hospitalization for HF (Zannad et al.”
BackgroundInfluentialSharma, A., Green, J. B., Dunning, A., Lokhnygina, Y., Al-Khatib, S. M., Lopes, R. D., Buse, J. B., Lachin, J. M., Van de Werf, F., Armstrong, P. W., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1091 · Cited by 80
Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis
Fisher, M., Petrie, M. C., Ambery, P., Donaldson, J., Ye, J., & McMurray, J. J. V. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00233-8 · Cited by 85
Zhang, Z., Chen, X., Lu, P., Zhang, J., Xu, Y., He, W., Li, M., Zhang, S., Jia, J., Shao, S., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0512-z · Cited by 78
“Studies focused on CV safety are available now and results indicate that incretin-based agents have no adverse effect on CV outcomes except saxagliptin increasing risk of heart failure hospitalization [14] and certain GLP-1As have shown CV protective effect [15, 16].”
BackgroundMethodInfluentialMarfella, R., Sardu, C., Calabrò, P., Siniscalchi, M., Minicucci, F., Signoriello, G., Balestrieri, M. L., Mauro, C., Rizzo, M. R., Paolisso, G., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13122 · Cited by 80
“GLP-1 levels (active GLP-1 [7-36] specific ELISA kit; Epitope Diagnostics, San Diego, California) were measured after an overnight fast (at 8:00 AM) and after breakfast in patients with diabetes.”
Kanie, T., Mizuno, A., Takaoka, Y., Suzuki, T., Yoneoka, D., Nishikawa, Y., Tam, W. W. S., Morze, J., Rynkiewicz, A., Xin, Y., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013650.pub2 · Cited by 127
Hiruma, S., Shigiyama, F., Hisatake, S., Mizumura, S., Shiraga, N., Hori, M., Ikeda, T., Hirose, T., & Kumashiro, N. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01228-3 · Cited by 87
“DPP-4 inhibitors increase the risk of hospitalizations due to heart failure [9, 51].”
BackgroundConcurrent diabetes and heart failure: interplay and novel therapeutic approaches
Karwi, Q. G., Ho, K. L., Pherwani, S., Ketema, E. B., Sun, Q., & Lopaschuk, G. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab120 · Cited by 90
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Davies, M. J., Drexel, H., Jornayvaz, F. R., Pataky, Z., Seferovic, P. M., & Wanner, C. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01575-9 · Cited by 83
“For instance, all three therapeutic classes are associated with relatively low risk of hypoglycaemic events, while patients treated GLP-1 RAs and SGLT2 inhibitors may benefit from weight loss [15, 27, 30, 32, 57, 103].”
BackgroundInfluentialDPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages
Brenner, C., Franz, W.-M., Kühlenthal, S., Kuschnerus, K., Remm, F., Gross, L., Theiss, H. D., Landmesser, U., & Kränkel, N. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.07.044 · Cited by 83
Zhao, H., Wei, R., Wang, L., Tian, Q., Tao, M., Ke, J., Liu, Y., Hou, W., Zhang, L., Yang, J., et al. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00017.2014 · Cited by 77
“However, data from two recent large cardiovascular end-point trials of dipeptidyl peptidase-4 inhibitors, saxagliptin and alogliptin, have shown no significant differences between the treatment and placebo groups in the incidence of pancreatic cancer (31, 39).”
ResultFu, A. Z., Johnston, S. S., Ghannam, A., Tsai, K., Cappell, K., Fowler, R., Riehle, E., Cole, A. L., Kalsekar, I., & Sheehan, J. (2016) · Diabetes Care · doi:10.2337/dc15-0764 · Cited by 78
Heart Failure With Preserved Ejection Fraction in Diabetes: Mechanisms and Management
Meagher, P., Adam, M., Civitarese, R., Bugyei‐Twum, A., & Connelly, K. A. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.02.026 · Cited by 85
Wang, Y., Han, D., Zhou, T., Chen, C., Cao, H., Zhang, J. Z., Ma, N., Liu, C., Song, M., Shi, J., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab316 · Cited by 77
Glucagon and heart in type 2 diabetes: new perspectives
Ceriello, A., Genovese, S., Mannucci, E., & Gronda, E. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0440-3 · Cited by 77
High glucose–induced endothelial progenitor cell dysfunction
Kang, H., Ma, X., Liu, J., Fan, Y., & Deng, X. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164117719058 · Cited by 83
Dawwas, G. K., Smith, S. M., & Park, H. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13477 · Cited by 76
“inhibitors comparably lowers uric acid and offer renoprotective effects, but these appear to be modest.(32) Results from our subgroup analyses suggest that the beneficial effects of use of SGLT2 inhibitors on cardiovascular risk occur irrespective of the presence of baseline CVD.”
BackgroundWorsening Heart Failure During the Use of DPP-4 Inhibitors
Packer, M. (2018) · JACC Heart Failure · doi:10.1016/j.jchf.2017.12.016 · Cited by 86
Driessen, J. H. M., van Onzenoort, H. A. W., Starup-Linde, J., Henry, R., Burden, A. M., Neef, C., van den Bergh, J. P., Vestergaard, P., & de Vries, F. (2015) · Calcified Tissue International · doi:10.1007/s00223-015-0037-y · Cited by 76
“Our results are also in keeping with a large clinical trial (n = 16,492) on the effect of a DPP4-I, saxagliptin, which showed no difference in risk of fracture with the use of DPP4-I use and placebo [24].”
ResultRecomendaciones preventivas cardiovasculares
Galán, Á. M. M., Cuixart, C. B., Álvarez, F. V., Pérez, J. N., Lobos-Bejarano, J. M., Sánchez-Pinilla, R. O., Rioboó, E. M., Banegas, J. R. B., Orozco‐Beltrán, D., & Gil-Guillén, V. F. (2012) · Atención Primaria · doi:10.1016/s0212-6567(12)70010-0 · Cited by 87
Al-Salameh, A., Chanson, P., Bucher, S., Ringa, V., & Becquemont, L. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.08.007 · Cited by 77
Morgan, C. L., Mukherjee, J., Jenkins‐Jones, S., Holden, S. E., & Currie, C. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12306 · Cited by 86
Cancer Biology and Prevention in Diabetes
Srivastava, S. P., & Goodwin, J. E. (2020) · Cells · doi:10.3390/cells9061380 · Cited by 83
Fadini, G. P., Bonora, B. M., Cappellari, R., Menegazzo, L., Vedovato, M., Iori, E., Marescotti, M. C., Albiero, M., & Avogaro, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3716 · Cited by 80
“In addition, we measured active human GLP-1 (GLP-1 [7–36 amide] and GLP-1 [7–37]) using a commercially available ELISA kit (catalog number EGLP-35K; Millipore).”
MethodYamada, H., Tanaka, A., Kusunose, K., Amano, R., Matsuhisa, M., Daida, H., Ito, M., Tsutsui, H., Nanasato, M., Kamiya, H., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0546-2 · Cited by 76
“In particular, the rate of hospitalization for heart failure was similar between sitagliptin and placebo treatments in the TECOS trial [13], despite the SAVOR-TIMI 53 trial showing that saxagliptin, another DPP-4 inhibitor, significantly increased the hospitalization rate [12].”
MethodResultLevelt, E., Gulsin, G. S., Neubauer, S., & McCann, G. P. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0724 · Cited by 85
New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
Dekkers, C. C. J., Gansevoort, R. T., & Heerspink, H. J. L. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-0992-6 · Cited by 82
Cardiovascular Disease in Diabetes Mellitus
Szuszkiewicz-Garcia, M., & Davidson, J. A. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.09.001 · Cited by 94
“007).(58) CAROLINA, a study comparing cardiovascular outcomes in patients on”
Self-citationKhan, S. S., Breathett, K., Braun, L. T., Chow, S. L., Gupta, D. K., Lekavich, C., Lloyd-Jones, D. M., Ndumele, C. E., Rodriguez, C. J., Allen, L. A., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001307 · Cited by 75
Bell, D. S. H., & Gonçalves, E. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13652 · Cited by 87
“Liraglutide had no effect on mortality or readmission for HF in either the diabetes or the non-diabetes group.155 Also, in the LEADER study, a large, randomized, blinded study with liraglutide, there was a non-significant 13% decrease (P = 0.14) in HAHF.21 In the LIVE trial, which also included patients with chronic s…”
BackgroundInfluentialIncretin physiology and pathophysiology from an A sian perspective
Cho, Y. M. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12305 · Cited by 81
Drug induced acute pancreatitis: Does it exist?
Tenner, S. M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i44.16529 · Cited by 82
Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure
Arturi, F., Succurro, E., Miceli, S., Cloro, C., Ruffo, M., Maio, R., Perticone, M., Sesti, G., & Perticone, F. (2016) · Endocrine · doi:10.1007/s12020-016-1166-4 · Cited by 78
Cardiovascular Protection in People With Diabetes
Stone, J. A., Houlden, R. L., Lin, P., Udell, J. A., & Verma, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.024 · Cited by 84
Self-citationGupta, S., & Sen, U. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104391 · Cited by 83
Glycaemic Control and Vascular Complications in Diabetes Mellitus Type 2
Maranta, F., Cianfanelli, L., & Cianflone, D. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_514 · Cited by 90
Chronic kidney disease in patients with diabetes mellitus
Nordheim, E., & Jenssen, T. G. (2021) · Endocrine Connections · doi:10.1530/ec-21-0097 · Cited by 89
Lorenzo-Almorós, A., Cepeda-Rodrigo, J. M., & Lorenzo, Ó. (2020) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2019.10.012 · Cited by 94
Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium
Wallner, M., Kolesnik, E., Ablasser, K., Khafaga, M., Wakula, P., Ljubojević-Holzer, S., Thon-Gutschi, E., Sourij, H., Kapl, M., Edmunds, N. J., et al. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.09.018 · Cited by 75
Effect of anti-diabetic drugs on bone metabolism: Evidence from preclinical and clinical studies
Adil, M., Khan, R. A., Kalam, A., Venkata, S. K., Kandhare, A. D., Ghosh, P., & Sharma, M. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.05.008 · Cited by 75
Time course and mechanisms of the anti‐hypertensive and renal effects of liraglutide treatment
von Scholten, B. J., Lajer, M., Goetze, J. P., Persson, F., & Rossing, P. (2015) · Diabetic Medicine · doi:10.1111/dme.12594 · Cited by 73
DPP‐4 inhibitors and risk of infections: a meta‐analysis of randomized controlled trials
Yang, W., Cai, X., Han, X., & Ji, L. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2723 · Cited by 77
Current perspectives on cardiovascular outcome trials in diabetes
on behalf of the D&CVD EASD Study Group, Schnell, O., Rydén, L., Standl, E., & Ceriello, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0456-8 · Cited by 74
“namely the SAVOR-TIMI, TECOS, ELIXA, EXAMINE, EMPA-REG, LEADER and SUSTAIN 6 trials [44-52].”
BackgroundMethodZhong, J., Gong, Q., Goud, A., Srinivasamaharaj, S., & Rajagopalan, S. (2015) · Journal of Diabetes Research · doi:10.1155/2015/606031 · Cited by 72
“The physiologic targets include GLP1, GLP2, brain natriuretic peptide (BNP), peptide YY, stromal-cell-derived factor-1 (SDF-1), erythropoietin, granulocyte colony-stimulating factor (G-CSF), and substance P (3) (4) (5) (6) (7) (8) (9) (10) (11) .”
BackgroundResultInfluentialXiao, C., Dash, S., Morgantini, C., Patterson, B. W., & Lewis, G. F. (2014) · Diabetes · doi:10.2337/db13-1654 · Cited by 72
Marx, N., McGuire, D. K., Perkovic, V., Woerle, H.-J., Broedl, U. C., von Eynatten, M., George, J. T., & Rosenstock, J. (2017) · Diabetes Care · doi:10.2337/dc17-0068 · Cited by 72
Self-citationChang, C., Yeh, Y., Chan, Y., Liu, J., Chang, S., Lee, H., Wu, L., Yen, K., Kuo, C.-T., & See, L. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0640-5 · Cited by 81
“SAVOR-TIMI53, and TECOS, all failed to show significant improvement in cardiovascular outcomes in type 2 diabetic patients treated with DPP4i [38, 42, 43].”
Cardiovascular Disease and Diabetic Kidney Disease
Maqbool, M., Cooper, M. E., & Jandeleit-Dahm, K. A. M. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.02.003 · Cited by 80
Metadata
- Authors
- Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., Cavender, M. A., Udell, J. A., Desai, N. R., Mosenzon, O., McGuire, D. K., Ray, K. K., Leiter, L. A., & Raz, I.
- Affiliations
- Brigham and Women's Hospital (US)
- The University of Texas Southwestern Medical Center (US)
- AstraZeneca (United States) (US)
- Bristol-Myers Squibb (United States) (US)
- Hadassah Medical Center (IL)
- St George's, University of London (GB)
- St. Michael's Hospital (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-03
- Volume
- 369
- Issue
- 14
- Pages
- 1317-1326
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2064130493
- Cited by
- 3,470
- References
- 38
- Citations by year
- 2026: 82 · 2025: 137 · 2024: 129 · 2023: 157 · 2022: 182 · 2021: 233 · 2020: 322 · 2019: 324 · 2018: 365 · 2017: 392 · 2016: 422 · 2015: 337 · 2014: 320 · 2013: 57
- FWCI
- 297.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion)
- Hispana (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Griffith Research Online (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- saxagliptin, type 2 diabetes, DPP-4 inhibitors, cardiovascular safety, cardiovascular outcomes, myocardial infarction, ischemic stroke, cardiovascular mortality, heart failure hospitalization, pancreatitis, non-inferiority, antidiabetic drugs, cardiovascular risk stratification, glycemic control
- MeSH terms
- Adamantane, Aged, Aged, 80 and over, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Dipeptides, Double-Blind Method, Female, Heart Failure, Hospitalization, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Pancreatitis, Kaplan-Meier Estimate, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.